Oncology Central

Viral cancer therapies: are they ready for combination with other immunotherapies?

In the field of immunotherapy, oncolytic viruses (OVs) hold a special place at the crossroad of various antitumor mechanisms. Due to their ability to specifically target and kill cancer cells without replicating in the healthy ones, they have been extensively studied over the last two decades for their direct cytotoxic properties; tens of RNA or DNA viruses exhibiting natural or engineered oncolytic properties have been demonstrated to exert antitumor effects, in vitro, in vivo and in patients, against a wide variety of human malignancies, including aggressive cancers such as multiple myeloma, metastatic melanoma or hepatocellular carcinoma [1]
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.